Teleflex ’ s NeuroTract touts UK Urolift decision

Teleflex (NYSE:TFX) subsidiary NeoTract said today that the UK Government selected the UroLift system, intended to treat patients with benign prostatic hyperplasia, as one of seven Accelerated Access Collaborative “Rapid Uptake Products.” The Wayne, Penn.-based company said that the system will now receive support from the Accelerated Access Collaborative which will increase its use by the UK’s NHS. The decision to include the device in the list follows its placement last year by NHS England as a recipient of the Innovation and Technology Tariff, which also helped support uptake of the treatment. “I am very pleased by this news. Having been involved in the initial European randomized clinical trial, the potential benefits of the UroLift System to both patients and the NHS quickly became very clear. What was evident from the beginning was that this is an effective day case procedure that, for the first time, preserves sexual function; we could offer most patients the likely prospect going home catheter-free; and they would experience a rapid improvement in symptoms and a return to normal activity with days rather than weeks as is the case for more standard surgical options. What we have learned in the NHS setting since the first procedures in 2014 is that the UroLift System has hugely helped us to improve the use of our resources. In my own Trust, we have been able to relocate the site of operation from the classical operating theatre to a procedure ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Urology Teleflex Source Type: news